Genetic prodrug activation therapy for pancreatic cancer
Ann N Y Acad Sci
.
1999 Jun 30:880:319-25.
doi: 10.1111/j.1749-6632.1999.tb09535.x.
Authors
A S Rigg
1
,
N R Lemoine
Affiliation
1
Imperial Cancer Research Fund Molecular Oncology Unit, Hammersmith Hospital, Imperial College School of Medicine, London, UK.
PMID:
10415876
DOI:
10.1111/j.1749-6632.1999.tb09535.x
No abstract available
Publication types
Review
MeSH terms
Adenocarcinoma / drug therapy*
Animals
Biotransformation
Genetic Therapy / methods*
Humans
Pancreatic Neoplasms / drug therapy*
Prodrugs / metabolism
Prodrugs / therapeutic use*
Substances
Prodrugs